InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Borisy Alexis. Insider active across 8 companies, notably Blueprint Medicines Corp. In total, 24 filings have been recorded. History available since 2 June 2021. The latest transaction was filed on 26 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Borisy Alexis
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报24 总计
1,191 股Common StockSEC:0001610717-26-000289:0
105,414 股Common StockSEC:0001193125-26-271300:0
3,902 股Common StockSEC:0001104659-25-069385:0
3,142 股0Common StockSEC:0001610717-25-000270:0
3,902 股@ US$128.12100.0% 占其流量Common StockSEC:0001415889-25-018075:0
6,250 股0Common StockSEC:0000950170-25-083903:0
4,248 股0Common StockSEC:0001610717-24-000375:0
4,800 股0Common StockSEC:0001610717-24-000360:0
2,242 股0Common StockSEC:0001415889-24-016980:0
6,250 股0Common StockSEC:0000950170-24-070851:0
2,091,672 股Common StockSEC:0001610717-23-000355:0
18,810,000 股Common StockSEC:0000899243-23-020290:0
2,600 股0Common StockSEC:0001415889-23-010258:0
5,200 股0Common StockSEC:0001610717-23-000135:0
5,000 股0Common StockSEC:0000899243-23-015016:0
2,600 股0Common StockSEC:0001415889-22-007130:0
5,200 股0Common StockSEC:0001567619-22-013106:0
312,612 股0Common StockSEC:0001209191-22-028956:0
312,612 股0Common StockSEC:0001209191-22-028424:0
18,810,000 股Common StockSEC:0000899243-21-049124:0
4,100 股0Common StockSEC:0000899243-21-037336:0
3,617 股0Common StockSEC:0001567619-21-012587:0
2,250 股0Common StockSEC:0001179110-21-006415:0
0Common StockSEC:0001179110-16-018851:0
24 条申报中的 24 条
About Borisy Alexis
Borisy Alexis is a declarant with 24 filings in total. In the recent filings tracked, the period runs from 2016-02-09 to 2026-06-23, with buy volume of EUR 0 and sell volume of EUR 0. He is a Director at Revolution Medicines, Inc., Blueprint Medicines Corp, Tango Therapeutics, Inc., Opko Health, INC. and Parabilis Medicines, Inc., and Executive Chairman at EQRx, Inc. The modal transaction nature is Attribution.
